Search Results - "Boudný, Miroslav"

Computational Design of Pore-Forming Peptides with Potent Antimicrobial and Anticancer Activities by Deb, Rahul, Torres, Marcelo D. T., Boudný, Miroslav, Koběrská, Markéta, Cappiello, Floriana, Popper, Miroslav, Dvořáková Bendová, Kateřina, Drabinová, Martina, Hanáčková, Adelheid, Jeannot, Katy, Petřík, Miloš, Mangoni, Maria Luisa, Balíková Novotná, Gabriela, Mráz, Marek, de la Fuente-Nunez, Cesar, Vácha, Robert

“…Peptides that form transmembrane barrel-stave pores are potential alternative therapeutics for bacterial infections and cancer. However, their optimization for…”
Get full text

Duplication of 8q24 in Chronic Lymphocytic Leukemia: Cytogenetic and Molecular Biologic Analysis of MYC Aberrations by Ondroušková, Eva, Bohúnová, Michaela, Závacká, Kristýna, Čech, Patrik, Šmuhařová, Petra, Boudný, Miroslav, Oršulová, Martina, Panovská, Anna, Radová, Lenka, Doubek, Michael, Plevová, Karla, Jarošová, Marie

“…Chronic lymphocytic leukemia (CLL) with cytogenetics findings, such as complex karyotype and deletions of TP53 or ATM , is associated with adverse clinical…”
Get full text

The Important Role of STAT3 in Chronic Lymphocytic Leukaemia Biology by Boudny, M, Trbusek, M

“…Signal transducer and activator of transcription (STAT) proteins are cytoplasmic transcription factors that transmit the signal of cytokines, hormones and…”
Get more information

ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias by Boudny, Miroslav, Trbusek, Martin

“…•ATR-CHK1 pathway is a promising therapeutic target for leukemia treatment.•ATR and CHK1 inhibition showed great results in preclinical testing in…”
Get full text

Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C‑Nucleosides by Khirsariya, Prashant, Pospíšil, Patrik, Maier, Lukáš, Boudný, Miroslav, Babáš, Martin, Kroutil, Ondřej, Mráz, Marek, Vácha, Robert, Paruch, Kamil

“…Histone methyltransferase DOT1L is an attractive therapeutic target for the treatment of hematological malignancies. Here, we report the design, synthesis, and…”
Get full text

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells by Boudny, Miroslav, Zemanova, Jana, Khirsariya, Prashant, Borsky, Marek, Verner, Jan, Cerna, Jana, Oltova, Alexandra, Seda, Vaclav, Mraz, Marek, Jaros, Josef, Jaskova, Zuzana, Spunarova, Michaela, Brychtova, Yvona, Soucek, Karel, Drapela, Stanislav, Kasparkova, Marie, Mayer, Jiri, Paruch, Kamil, Trbusek, Martin

“…Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic…”
Get full text

Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs by Hoferkova, Eva, Seda, Vaclav, Kadakova, Sona, Verner, Jan, Loja, Tomas, Matulova, Kvetoslava, Skuhrova Francova, Hana, Ondrouskova, Eva, Filip, Daniel, Blavet, Nicolas, Boudny, Miroslav, Mladonicka Pavlasova, Gabriela, Vecera, Josef, Ondrisova, Laura, Pavelkova, Petra, Hlavac, Krystof, Kostalova, Lenka, Michaelou, Androniki, Pospisilova, Sarka, Dorazilova, Jana, Chochola, Vaclav, Jaros, Josef, Doubek, Michael, Jarosova, Marie, Hampl, Ales, Vojtova, Lucy, Kren, Leos, Mayer, Jiri, Mraz, Marek

“…Several in vitro models have been developed to mimic chronic lymphocytic leukemia (CLL) proliferation in immune niches; however, they typically do not induce…”
Get full text